Q3 2024 · 13F-HR
Cormorant Asset Management, LPholdings as filed
Filed 2024-11-14 · accession 0001583977-24-000006
$1.89B
Reported value
45
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $428.3M | 22.7% | 8,494,151 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $114.3M | 6.06% | 1,000,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $104.4M | 5.54% | 1,250,000 | Common | SOLE |
| 54300N103 | — | LONGBOARD PHARMACEUTICALS IN | $93.0M | 4.93% | 2,790,462 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $90.9M | 4.82% | 3,406,534 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $66.5M | 3.53% | 8,325,000 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $60.2M | 3.19% | 2,940,921 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $56.2M | 2.98% | 1,100,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $50.1M | 2.65% | 870,000 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $49.0M | 2.60% | 2,375,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $48.2M | 2.56% | 1,050,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $47.7M | 2.53% | 1,050,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $47.3M | 2.51% | 1,858,351 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $41.0M | 2.17% | 2,470,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $41.0M | 2.17% | 2,561,600 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $37.0M | 1.96% | 740,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $36.8M | 1.95% | 975,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $36.5M | 1.94% | 500,000 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $36.1M | 1.91% | 3,570,872 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $35.9M | 1.91% | 400,000 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $33.9M | 1.80% | 1,629,529 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $30.4M | 1.61% | 2,909,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $27.2M | 1.44% | 1,466,460 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $24.5M | 1.30% | 2,130,000 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $22.9M | 1.22% | 2,147,396 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $21.8M | 1.16% | 1,182,563 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $21.6M | 1.15% | 2,325,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $21.0M | 1.11% | 400,000 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $20.1M | 1.07% | 401,963 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $19.7M | 1.04% | 1,550,000 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $19.1M | 1.01% | 1,450,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $18.2M | 0.96% | 700,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $16.4M | 0.87% | 500,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $13.8M | 0.73% | 585,462 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $11.5M | 0.61% | 342,465 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $8.9M | 0.47% | 265,826 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $7.3M | 0.39% | 400,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $6.6M | 0.35% | 1,000,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $5.2M | 0.28% | 427,163 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $4.5M | 0.24% | 107,344 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $4.0M | 0.21% | 593,043 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $2.6M | 0.14% | 1,394,336 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $1.7M | 0.09% | 350,000 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $1.6M | 0.08% | 103,633 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $998,468 | 0.05% | 496,750 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.